The U.S. Food and Drug Administration (FDA) released the MyStudies app, a new mobile technology to foster the collection of real world evidence via patients’ mobile devices. Real world data can be collected from a variety of sources, such as electronic health records, claims and billing activities, and product and disease registries, as well as from patient-generated data including in home-use settings, or from data gathered from other sources, such as mobile devices.
The FDA partnered with Kaiser Permanente on a pilot study to measure the functionality and engagement of the MyStudies app. Based on the successful outcome of the study, the FDA is now releasing the open source code and technical documents that will allow researchers and developers to customize and use the FDA’s newly created MyStudies app to expand the diversity of health information available for clinical trials and studies, while directly capturing the perspective of patients. By providing the open source code, the agency is providing a tool that sponsors and developers can adapt to advance their specific clinical trial and real world evidence needs, while also remaining compliant with the FDA’s regulations and guidance for data authenticity, integrity and confidentiality.
Read more:
- FDA’s MyStudies Application: https://www.fda.gov/Drugs/ScienceResearch/ucm624785.htm
- Related FDA news release: https://www.fda.gov/NewsEvents/Newsroom/FDAInBrief/ucm625228.htm